A new CRISPR-based strategy turns cancer cells' own mutant transcripts against them, opening a potential route to one of oncology's most stubborn...
Alpha-1 antitrypsin deficiency (AATD) has turned into the most crowded proving ground in genetic medicine, with five editing companies reporting fresh...
AIRNA has taken a different route to correcting the genetic lesion behind alpha-1 antitrypsin deficiency (AATD). Its oligonucleotide AIR-001 restored...
Scribe Therapeutics is preparing to take its first cardiometabolic programme into the clinic in mid-2026, positioning STX-1150 as a potentially...
A novel genome-editing platform addresses one of the field's most constant challenges – how to insert kilobase-scale DNA into living cells without...
The US FDA has issued a Study May Proceed notification for PBGENE-DMD, Precision BioSciences' investigational in vivo gene-editing therapy for...
nChroma Bio has received regulatory clearance in Hong Kong to initiate a Phase 1/2 clinical trial of its lead candidate CRMA-1001, marking the first...
Regeneron Pharmaceuticals and Tessera Therapeutics have formed a global partnership to develop and commercialise TSRA-196, Tessera’s lead in vivo Gene...
